Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 8/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397495 | 1.00 | ATM (0.41) | ATMNAMPTTSHRALOX15GPR119 | |
| SCHEMBL22440518 | 1.00 | ATM (0.41) | ATMNAMPTTSHRALOX15GPR119 | |
| SCHEMBL29832106 | 1.00 | ATM (0.41) | ATMNAMPTTSHRALOX15GPR119 | |
| SCHEMBL29832077 | 1.00 | ATM (0.41) | ATMNAMPTTSHRALOX15GPR119 | |
| SCHEMBL27193052 | 1.00 | ATM (0.41) | ATMNAMPTTSHRALOX15GPR119 | |
| SCHEMBL23902047 | 1.00 | ATM (0.41) | ATMNAMPTTSHRALOX15GPR119 | |
| SCHEMBL23046046 | 0.91 | NAMPT (0.40) | ATMNAMPTGPR119KDM1AMAPK1 | |
| SCHEMBL23046045 | 0.91 | NAMPT (0.40) | ATMNAMPTGPR119KDM1AMAPK1 | |
| SCHEMBL21940706 | 0.91 | NAMPT (0.40) | ATMNAMPTGPR119KDM1AMAPK1 | |
| SCHEMBL21940884 | 0.91 | NAMPT (0.40) | ATMNAMPTGPR119KDM1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073521-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
| US-20220073521-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
| WO-2020108590-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | 上海拓界生物医药科技有限公司 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073521-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | PTPN5, PTPN11, PTPN1 | ATM 2186/4885NAMPT 100/4885TSHR 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.